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ABSTRACT
Objectives: The objectives of the study were to study the prevalence of painful diabetic peripheral neuropathy (PDPN) in patients with type-2 
diabetes and to access the health-related quality of life of patient by collecting and documenting the information of patient using sf-15 questionnaire.
Methods: The present study involves prospective analysis of quality of life in both men and women with PDPN with type-2 diabetes. The methodology 
involves collection and documentation of patients medical and medication history, blood glucose levels, and duration of diabetes. Further, the quality 
of life of patient is documented using Michigan neuropathic scaling instrument (sf-15 questionnaire) through which we can assess the impact of PDPN.
Results: It can be seen that there are no significant changes in the prevalence of PDPN when compared gender wise and based on age, but there are 
an extremely statistically significant (*p<0.05) values obtained when the presence of PDPN is compared between duration of diabetes.
Conclusion: Patients with duration of diabetes type-2 between 5 and 10 years are mostly presented with PDPN. Early detection, nutritious diet, and 
patient counseling help in management of PDPN.
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INTRODUCTION
Peripheral neuropathy is the most common complication of 
type-2 diabetes [1]. Peripheral neuropathy can present as loss of 
sensation which may cause foot ulcers, which is the leading cause 
of amputations [2]. Peripheral neuropathy may be asymptomatic. It 
may have both negative and positive symptoms; negative symptoms 
include loss of sensation and loss of strength and positive symptoms 
include pain, which is then termed as painful diabetic peripheral 
neuropathy (PDPN) [3]. PDPN can last for years and severely 
impair quality of life of patients when left untreated [4]. Long-
term use of metformin may cause nerve damage which leads to 
neuropathy with both positive and negative symptoms [5]. Vitamin 
B12 supplementation may help in restoring nerve function and also 
reduction of neuropathic pain [6].
Mark Davies have conducted a cross-sectional descriptive study “the 
prevalence, severity, and impact of PDPN in type-2 diabetes” containing 
two phases, and concluded that the study showed a prevalence of PDPN 
of 26.4%. Having PDPN has a significant negative effect on quality of 
life, and increasing neuropathy is associated with an increasing risk of 
developing PDPN [7]. Deepika Bansal conducted a prospective study 
called “prevalence and risk factors of the development of peripheral 
neuropathy in type-2 diabetes mellitus in tertiary care unit” and 
concluded the study showed a high prevalence (29.2%) of DPN among 
north Indian type 2 diabetes mellitus patients. Thus, timely screening 
with earlier detection and intervention would be useful in preventing 
the progression of neuropathy [8].
The main aim of this study is to assess the quality of life of patients with 
PDPN and its impact on their daily life and determine the prevalence 
of PDPN in patients with type-2 diabetes. The impact of PDPN can be 
determined using score obtained by Michigan neuropathic scale (mnsi 
sf-15 questionnaire).
MATERIALS AND METHODS
The study is carried out in a tertiary care hospital.
Study period
The study of period was 6 months.
Study instrument
Case report form, MNSI (sf-15 questionnaire).
Inclusion criteria
All male and female patients aged above 30 years with type-2 diabetes 
were included in this study.
Exclusion criteria
Type 1 diabetes mellitus, gestational diabetes patients, lactating 
mother, and chronically ill patients were excluded from the study.
Methods
Study design
This method involves prospective analysis of quality of life of both 
male and female patients with PDPN with type-2 diabetes. The 
study is carried out by collection and documentation of general 
information of patient including personal history, medical and 
medication history, duration of diabetes, and blood glucose levels. 
The quality of life of patient and impact of pain is documented using 
MNSI questionnaire.
Study instrument
MNSI questionnaire (part-1) include consists of 15 “yes or no” 
questions on foot sensation including pain, numbness, and temperature 
sensitivity. The information is collected from each and every patient. 
Finally, the documented questionnaire is documented and evaluated 
for the presence or absence of PDPN. The study was conducted after 
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obtaining informed consent form from the patient. This study was 
approved by the institutional ethics committee IEC/DOPV/2016/14.
RESULTS
The following results were obtained when the data were collected from 
the patient.
Of 100 type-2 diabetic patients involved in the study, 57 patients 
have PDPN (male - 26, female - 31) and 43 patients do not have PDPN 
(male - 17, female - 26) (Table 1 and Fig. 1).
Of 100 patients, 57 patients are reported with PDPN where 16 patients 
(28%) were in age group of 35–45 years, 20 patients (35%) were in 
age group of 46–55 years, and 21 patients (36%) were in age group of 
56–65 years (Table 2 and Fig. 2).
Of 100 diabetic patients, patients who are having diabetes from up 
to 10 years, 30 members have presented with PDPN and 34 patients 
do not have PDPN. Patients who are having diabetes from more than 
10 years, 27 have presented with PDPN and 9 patients do not have 
PDPN (Table 3 and Fig. 3).
Table 4 and Fig. 4 summarizes there is no significance of the prevalence 
of PDPN when related to gender, in the given population. With 95% 
confidence interval (CI) *p=0.5432 [NS], two-sided study using Chi-
square, statistically not significant (α<0.05).
Table 5 and Fig. 5 summarizes there is no significance of the prevalence 
of PDPN when related to age group in given population. With 95% CI 
*p=0.2665 [NS], two-sided study using Chi-square, statistically not 
significant (α<0.05).
Table 6 and Fig. 6 summarizes there is high significance of the presence 
of PDPN in the given population, as most of the patients participated 
in study belonged to group having diabetes for <10 years. With 95% 
CI *p=0.0064, two-sided study using Chi-square, statistically significant 
(α<0.05, p=0.0064).
DISCUSSION
PDPN is caused due to nerve damage [9]. As patients with type-2 
diabetes are mostly prescribed with metformin for regulating the sugar 
levels, long-standing use of metformin is also one of the root causes of 
loss of nerve function which causes malabsorption of Vitamin B12 [10]. 
Low serum levels of Vitamin B12 are observed in patients who take 
2 g of metformin per day for at least 2 years [11]. Uncontrolled sugar 
levels in blood also causes nerve damage leading to neuropathy, but 
sugar levels can be controlled using hypoglycemic agents on time and 
maintaining healthy food habits and regular exercise [12] Although the 
patients with poor economic status are given with free treatment and 
vitamin supplements, lack of knowledge regarding the use of the drug, 
and less patient education, many patients with type-2 diabetes fail to 
take nutritious food and vitamin supplementations, especially B12 [13]. 
Results of the project show that a total of 100 diabetic patients 57 are 
diagnosed to have PDPN presenting a prevalence of 57%, 95% CI of 
studied sample, these results were similar with the results reported by 
dr. farooq ahmed (vol. 88 no. 16 Supplement P4.050) [14]. The mean 
age for the presence of PDPN in type-2 diabetic patients is 51.3 years. 
Female patients are reported relatively high than male patients. Most of 
the patients with PDPN are in age group of 51–65 years [15]. Patients 
who are having diabetes for more than 10 years are presented with less 
symptoms of PDPN and most of the patients with PDPN have diabetes 
for <10 years [16]. This is due to improper intake of medication, lack 
of nutritional intake, lack of B12 supplementation, and many such 
factors [17]. Patients with diabetes for more than 10 years have been 
taking proper B12 supplementation and limited amount of food which 
made them lead a healthy lifestyle. We can reduce the prevalence of 
PDPN by educating the patients regarding regular medication intake, 
Table 1: Presence and absence of PDPN in patients with type‑2 
diabetes
Gender Patients with PDPN Patients without PDPN
Male 26 17
Female 31 26
PDPN: Painful diabetic peripheral neuropathy
Table 2: Age‑based population distribution in patients with 
PDPN




PDPN: Painful diabetic peripheral neuropathy
Table 3: Comparison of duration of diabetes and presence of 
PDPN
Duration (years) Presence of PDPN Absence of PDPN
<10 30 34
>10 27 9
PDPN: Painful diabetic peripheral neuropathy
Table 4: Prevalence of PDPN in relation to gender in population
Gender Patients with PDPN Patients without PDPN Total
Male 26 17 43
female 31 26 57
PDPN: Painful diabetic peripheral neuropathy
Table 5: Prevalence of PDPN in relation with age group





35–50 23 22 45
51–65 34 21 55
PDPN: Painful diabetic peripheral neuropathy
Table 6: Prevalence of PDPN in relation with duration of type‑2 
diabetes





<10 30 34 64
>10 27 9 36
PDPN: Painful diabetic peripheral neuropathy
Fig. 1: Presence and absence of painful diabetic peripheral 
neuropathy in patients with type‑2 diabetes
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nutritional intake to be taken, maintaining glucose levels in the body, 
and modifications regarding lifestyle.
CONCLUSION
Patients with type-2 diabetes for more than 2 years with poor economic 
status lacked proper nutritional supplementation, especially Vitamin 
B12, which is leading cause of neuropathy. PDPN showed a negative 
impact on patients’ quality of life and effected the basic regular activities 
performed by the patient.
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